MSD (Merck & Co) has forged a partnership with British artificial intelligence (AI)-powered biotech Isomorphic Labs, which will see the pair collaborate on cancer drug development as the former looks to offset the looming patent cliff of its blockbuster checkpoint inhibitor Keytruda (pembrolizumab). 

Though precise details were not disclosed, MSD did note that the duo will band together to discover therapeutic small molecules against a specific oncology target of strategic importance.  

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

To further this mission, Isomorphic will feed MSD’s proprietary data sets into its drug design engine, IsoDDE, which will help the biotech to design and deliver molecular designs for new drug candidates faster than traditionally possible. Isomorphic will also take the lead on performing computer-based simulations to predict how effective a drug may be – potentially boosting the likelihood of a candidate’s success in the clinic. 

In exchange for an undisclosed upfront payment and potential research, development, regulatory and commercial milestones, as well as tiered royalties on potential net sales, MSD will secure the rights to any resulting fruits of this collaboration – with the US pharma giant taking the helm on preclinical and clinical development, as well as the manufacturing and commercialisation of any drugs created. 

Additionally, Isomorphic has the choice to co-fund development activities around resulting drugs to secure elevated royalties on therapies developed in tandem with MSD. 

MSD and Isomorphic ink this partnership a little after the latter made history by snagging the largest Series C raise in biotech history – securing $5bn to advance its range of AI-developed candidates across several modalities and therapeutic areas closer to the clinic. 

It also comes as MSD faces significant revenue losses through the impending patent expiry of its best-selling asset, Keytruda, which pulled in $8.6bn across its intravenous and subcutaneous formulations (Keytruda QLEX) in Q3 2026. 

With Keytruda revenues set to dip, MSD is now looking to the potential of several late-stage assets – including the Moderna co-developed cancer vaccine intismeran autogene, which analysts are touting as a potentially strong commercial opportunity following the drug’s late-stage win in adjuvant melanoma. 

Analysts are also taking a growing interest in antibody-drug conjugate (ADC), sacituzumab tirumotecan (sac-TMT), which has demonstrated notable promise across a range of cancers thus far in late-stage trials. The latest win for the TROP2-directed therapy was in a type of stomach cancer, with the drug having met its primary endpoint of overall survival (OS) in the third-line-plus metastatic gastroesophageal adenocarcinoma setting. 

MSD is bolstering its early-stage pipeline to seek more mid-to-long-term growth, with the company having inked a $2.1bn cancer licensing deal with Chinese biotech SciBrunch Therapeutics focused on its KRAS(ON) inhibitor in September 2026. The pharma giant pens this agreement as KRAS-targeting therapies create a buzz in the sector, with Revolution Medicines’ next-generation RAS inhibitor Rasonque (daraxonrasib) securing landmark US and European approvals in pancreatic cancer during August and November, respectively.